Want to see HK:2325 full AI Analyst Report?
2325 Stock Chart & Stats
HK$0.99
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.99
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.55 - HK$2.50
Previous CloseN/A
Volume10.00K
Average Volume (3M)1.61M
Market Cap
HK$397.60M
Enterprise Value-HK$610.86
Total Cash (Recent Filing)HK$1.70B
Total Debt (Recent Filing)HK$692.31M
Price to Earnings (P/E)109.8
Beta0.14
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.15%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding621,250,500
10 Day Avg. Volume4,171,850
30 Day Avg. Volume1,613,200
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)0.45
Price to Sales (P/S)0.87
P/FCF Ratio2.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$884.18M
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistently positive and rising operating cash flow and markedly higher free cash flow in 2025 provide durable internal funding. This strengthens liquidity, supports reinvestment or debt reduction, and reduces reliance on external capital across several quarters to years.
Operating Profitability ReboundA renewed EBIT margin near 15% signals improved core business efficiency and cost control. If sustained, this operating leverage can translate into structurally higher cash generation and better ability to withstand revenue pressure over the medium term.
Balance Sheet RepairMeaningful reduction in leverage versus 2024 improves financial flexibility and lowers refinancing risk. A sizable equity base provides a buffer, enabling strategic choices (capex, M&A, R&D) without immediate capital raises, supporting resilience over upcoming quarters.
Bears Say
Multi-year Revenue DeclineSustained top-line contraction erodes scale, weakens bargaining power and distribution economics, and limits the firm's ability to convert operating margin gains into long-term profit growth. Persistent revenue shrinkage threatens competitive positioning over many quarters.
Volatile Profitability And Weak ROEHighly variable profitability and near-zero ROE indicate poor shareholder value creation and inconsistent returns on capital. This undermines confidence in management's capital allocation and limits ability to attract long-term funding without clear profit recovery.
Earnings Quality MismatchA divergence where cash flow is strong but reported net income is very low suggests one-off items or accounting effects. Persistent mismatches complicate forecasting and signal that earnings may not reliably reflect sustainable business performance.
Yunkang Group Limited News
2325 FAQ
What was Yunkang Group Limited’s price range in the past 12 months?
Yunkang Group Limited lowest stock price was HK$0.55 and its highest was HK$2.50 in the past 12 months.
What is Yunkang Group Limited’s market cap?
Yunkang Group Limited’s market cap is HK$397.60M.
When is Yunkang Group Limited’s upcoming earnings report date?
Yunkang Group Limited’s upcoming earnings report date is Aug 28, 2026 which is in 7 days.
How were Yunkang Group Limited’s earnings last quarter?
Yunkang Group Limited released its earnings results on Mar 30, 2026. The company reported HK$0.109 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Yunkang Group Limited overvalued?
According to Wall Street analysts Yunkang Group Limited’s price is currently Overvalued.
Does Yunkang Group Limited pay dividends?
Yunkang Group Limited pays a Annually dividend of HK$0.02 which represents an annual dividend yield of 2.15%. See more information on Yunkang Group Limited dividends here
What is Yunkang Group Limited’s EPS estimate?
Yunkang Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yunkang Group Limited have?
Yunkang Group Limited has 621,250,500 shares outstanding.
What happened to Yunkang Group Limited’s price movement after its last earnings report?
Yunkang Group Limited reported an EPS of HK$0.109 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.22%.
Which hedge fund is a major shareholder of Yunkang Group Limited?
Currently, no hedge funds are holding shares in HK:2325
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yunkang Group Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.35%
Trailing 12-Months
Company Description
Yunkang Group Limited
Yunkang Group Limited, established in 2008 and headquartered in Guangzhou, People's Republic of China, operates as a comprehensive provider of medical operational services. The company offers a wide range of diagnostic testing solutions to medical institution alliances, which encompass assisting with the setup and enhancement of diagnostic centers, developing standard operating procedures for testing, delivering expert diagnostic consultations and staff training, sourcing necessary equipment, implementing smart Internet of Things technology, and providing logistics support. For diagnostic outsourcing, Yunkang Group conducts diverse tests, including pathology examinations; infectious disease diagnostics for conditions such as hepatitis B, tuberculosis, human papillomavirus, Epstein-Barr virus, rabies, and respiratory pathogens (via nucleic acid testing); genetic and reproductive health screenings; and routine diagnostic assessments for chronic ailments like kidney, blood, autoimmune, and endocrine metabolic diseases. Furthermore, the company caters to financial institutions and insurance firms by offering personalized diagnostic testing, medical report interpretation, and hospital referral services. Yunkang Group's capabilities also extend to information technology, medical logistics, procurement of medical equipment, healthcare technology development, and various project investments. These services are delivered through its network of independent clinical laboratories and integrated on-site diagnostic facilities.
Technical Analysis
EC Healthcare
―
Mediwelcome Healthcare Management & Technology Inc.
―
Yonghe Medical Group Co., Ltd.
―
Hospital Corporation of China Ltd
―
Town Health International Medical Group Ltd.
―